Search for a trial

A Phase 3, Randomized, Double-blind Active-controlled Study
Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary
Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential
Thrombocythemia Myelofibrosis (Post-PV/ET MF)

The primary objective of this study is:* The primary objective of this clinical trial will be to determine the efficacy of MMB compared with ruxolitinib as measured by splenic response rate at Week 24 (SRR24).The secondary objectives of this study…

The effectiveness of Pulsed Electromagnetic Field in the treatment of medial tibial stress syndrome: a pilot study.

Primary Objective: - Determine the effectiveness of a treatment with pulsed electromagnetic field therapy in patients with medial tibial stress syndrome (MTSS).Secondary Objective(s): - Determine the feasibility of the study design.- Determine the…

Bone augmentation with autologous adipose tissue-derived mesenchymal stem cells and calcium phosphate carriers in the human maxillary sinus floor elevation model

> Primary Objective:This is a pilot study, aiming at the clinical evaluation with respect to safety and feasibility of a one-step surgical procedure for maxillary sinus floor augmentation for the placement of dental implants, using a ceramic…

A proof-of-concept study of SB-751689 in male and female with a fractured distal radius.

To evaluate the effects of SB-751689 on the time to radiographic healing, defined as the interval in days between the occurrence of the radial fracture and the time of complete bridging and/or disappearance of fracture line at 3 of the following 4…

A phase 1 double blind, placebo controlled study of ALX-0141 single dose subcutaneous administration in healthy post-menopausal women

- to determine the maximum tolerated dose (MTD) and/or biological effective dose (BED) after single s.c. administration of ALX-0141 - to determine the safety and tolerability of escalating single doses of ALX-0141 in healthy postmenopausal women

Efficacy of post-operative pain management with intralesional ropivacaine after subacromial decompression

The researchquestions of this study are:1. What is the efficacy of treatment of postoperative pain after subacromial decompression with a subacromial catheter with ropivacaine versus placebo?2. What are the differences in costs per patient and in…

Reduction of Bone Morbidity using Oral Bisphosphonate in Fibrous Dysplasia of Bone

To evaluate the effect of the bisphosphonate risedronate (together with vitamin D and calcium or vitamin D calicum and phosphate in patients with renal phosphate wasting) on bone pain and the evolution of osteolytic bone lesions in patients with FD.

Pamidronate for pain in adult chronic nonbacterial osteitis (PAM-CNO): a randomized, double-blind, placebo-controlled trial

This study has been transitioned to CTIS with ID 2023-510309-16-00 check the CTIS register for the current data. The primary objective to demonstrate that in CNOpatients with pain 3-monthly treatment with pamidronate will result in significant…

Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva

This study has been transitioned to CTIS with ID 2023-508350-26-00 check the CTIS register for the current data. Primary ObjectiveThe primary efficacy objective of the study is to assess the effect of garetosmab (10 mg/kg) versus placebo on the…

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

This study has been transitioned to CTIS with ID 2024-517528-20-00 check the CTIS register for the current data. Primary objective:• To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat (ITT) population as measured by…

Phase III, pivotal, multicentre, randomised, double-blind controlled Study to evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head.

To determine the efficacy and safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of early stage non-traumatic osteonecrosis of the femoral head.